Diffuse large B-cell lymphoma with MYC and BCL2 coexpression often carries a poor prognosis. However, a major randomized clinical trial shows that tucidinostat plus R-CHOP significantly improves outcomes for these high-risk patients. Specifically, this oral histone deacetylase inhibitor selectively targets epigenetic pathways that drive cancer progression. Consequently, this novel combination therapy offers a powerful first-line option for newly diagnosed individuals.
Clinical Evidence for Tucidinostat plus R-CHOP
To evaluate this therapy, researchers therefore conducted a randomized phase 3 trial across forty centers in China. They enrolled 423 eligible patients with newly diagnosed double-expressor lymphoma. Furthermore, investigators randomized participants to receive either tucidinostat or placebo, combined with six standard R-CHOP cycles. Thereafter, patients achieving a complete response received maintenance therapy for up to 24 weeks.
Consequently, during a median follow-up of 41.3 months, the experimental group demonstrated superior survival metrics. Specifically, patients receiving tucidinostat plus R-CHOP experienced a 28% lower risk of disease progression, relapse, or death. Indeed, the 2-year event-free survival rate reached 60.3% compared to 50.5% in the placebo group. Additionally, the complete response rate significantly increased to 73.0% from 61.8% in the control arm.
Safety Profile and Manageability
Although the combination therapy showed clear efficacy, the addition of tucidinostat also increased treatment-related toxicity. For instance, the tucidinostat group experienced higher rates of hematological adverse events like neutropenia and thrombocytopenia. However, clinicians successfully managed these adverse events using standard supportive care and dose adjustments. As a result, the treatment discontinuation rates remained low and comparable between both study groups.
Therefore, this trial establishes a manageable safety profile for the regimen in patients with newly diagnosed disease. In addition, the study marks the first time an epigenetic modulator has successfully improved outcomes in diffuse large B-cell lymphoma. Ultimately, this milestone clinical trial provides a new therapeutic standard that directly targets coexpressed MYC and BCL2 oncoproteins.
Frequently Asked Questions
Q1: What is MYC/BCL2 double-expressor lymphoma, and why is it difficult to treat?
Double-expressor lymphoma is a high-risk subtype of diffuse large B-cell lymphoma. This subtype features the coexpression of MYC and BCL2 proteins. Historically, patients with this subtype experience poor prognosis and low survival rates after standard first-line R-CHOP therapy.
Q2: How does tucidinostat plus R-CHOP improve patient outcomes?
Adding tucidinostat to R-CHOP significantly improves event-free survival and complete response rates. Specifically, the combination reduces the risk of disease progression, relapse, or death by 28%. Additionally, it increases the complete response rate to 73.0% compared to 61.8% with R-CHOP alone.
Q3: What are the main side effects of adding tucidinostat to R-CHOP?
The addition of tucidinostat increases treatment-related toxicities, particularly hematological side effects such as neutropenia and thrombocytopenia. However, clinicians can successfully manage these side effects using standard supportive care, and discontinuation rates remain low.
References
- Xu PP et al. Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial. JAMA. 2026 May 19. doi: undefined. PMID: 42018318.
- ClinicalTrials.gov. Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL (NCT04231448).
- OncLive. Chidamide Plus R-CHOP Approved in China for MYC/BCL2–Expressing DLBCL. Published April 30, 2024.